Month: September 2017

IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase

Revenue for the fourth quarter of fiscal 2017 was $1.37 million, a 22% increase compared to $1.12 million revenue for the fourth quarter of fiscal 2016 and a 7% increase compared to revenue of $1.28 million in the third quarter of fiscal 2017.

IsoRay Announces “Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial” Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference

The poster, entitled “Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial”, was presented by Dr. Brian Moran, Medical Director, Prostate Cancer Foundation of Chicago, Westmont, Illinois.

Viewpoint CSO “Spotlight Speaker” at World Molecular Imaging Congress

September 15, 2017 | Philadelphia, PA.

Viewpoint Co-Founder and Chief Science Officer Michael Schultz, PhD was invited to speak at the Spotlight Session – Advancing Drug Discovery conference session of the World Molecular Imaging Congress. The spotlight sessions of the conference are designed to give attendees perspectives on current issues in molecular imaging. Dr. Schultz was invited to present his perspectives on the key role that University start-ups and small biotech companies play in advancing molecular imaging for drug development.

“It is very exciting for Viewpoint to be recognized by the World Molecular Imaging Society as a successful company. It was a remarkable session with perspectives ranging from large Pharma to contract research organizations. I was delighted to take part.”–MICHAEL SCHULTZ, Viewpoint Co-Founder and Chief Science Officer

Viewpoint Awarded $2 Million NCI Contract

September 8, 2017 | Coralville, IA.

Viewpoint Molecular Targeting, Inc., a University of Iowa start-up pharmaceutical company that has developed a novel therapy and companion diagnostic for metastatic melanoma, has been awarded a Phase II Small Business Innovation Research (SBIR) Contract Award valued at $2 million from the National Institutes of Health (NIH) to support pre-clinical studies of its lead product, VMT01. The company has successfully secured $900K in previously awarded Phase I SBIR grants and contracts. “We value the NIH’s continued recognition of the importance of our products and its support of our development program. We are excited with the progress we are making to bring our products forward,” said Edwin Sagastume, Viewpoint Biochemical Engineer and University of Iowa graduate.

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting develops therapies and diagnostics for cancer, with a focus on metastatic melanoma and neuroendocrine tumors. It’s lead products, VMT01 and VMT-α-NET, are injectable radiopharmaceuticals. The products can be used to determine the location and extent of cancerous tumors in the body and then the therapeutic forms can be used to direct a therapeutic dose of radiation precisely to cancer cells in the body. This represents a new class of drugs called theranostics.

Viewpoint has successfully secured over $6 million through seed capital investments, NIH SBIR grants, Iowa Economic Development Authority Demonstration Funds, Innovation Iowa Corporation Matching Funds, and business pitch competition victories. The current award sends the company into clinical trials for its lead products, with other cancer therapy products in the development pipeline.

About NIH SBIR Program

The NIH SBIR program funds early stage small businesses that are seeking to commercialize innovative biomedical technologies. This competitive program helps small business participate in federal research and development to develop life-saving technologies and create jobs.

See more: UIHC

Our Favorite Patient Resources

Every 3.3 minutes a man is diagnosed with prostate cancer. Many of these men know very little about the prostate, what diagnosis will entail, and most importantly, options for treatment.

Scroll to top